Isomab Ltd is a UK-based startup founded in 2022 that is focused on a unique approach to develop isoform-specific antibodies for treating diseases with limited or no treatment options. Their primary product, ISM-001, specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A). This innovation is based on 20 years of research by the company's founders. IsomAb recently secured a £7.50M Seed Round investment on 20th February 2024 from prominent investors including Broadview Ventures, SCVC, and MEIF Proof-of-Concept & Early Stage Fund. The company's breakthrough approach and the support of reputable investors position IsomAb as a potential game-changer in the biotech industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | £7.50M | 3 |
|
20 Feb 2024 |
| Pre Seed Round | Unknown | 1 |
|
01 Jan 2023 |
We care about your data, and we'd love to use cookies make your experience better.
